Method development and validation for the estimation of imatinib mesylate in tablet dosage form by rp-hplc method

RP-HPLC method was developed by Imatinib mesylate in bulk and pharmaceutical dosage form maximum absorbance was found at 230nm and peak purity was excellent. Imatinib mesylate is a protein-tyrosine kinase inhibitor, Inhibits the abnormally functioning Bcr-Ab1 tyrosine kinase which is produced by the Philadelphia chromosome abnormality found in chronic myeloid leukaemia (CML). It is found that the method of RP-HPLC with UV-detection system for the analysis of Imatinib mesylate is straight forward and applied in qualitative and quantitative analysis. This method is simple, rapid, selective and inexpensive. The percent recovery of drug ranged from 99.0 to100.4.The proposed method for estimation of selected drug Imatinib mesylate was successfully applied in pharmaceutical formulation.